Zydus Lifesciences Ltd.

Cadila Healthcare, a global pharmaceuticals company, and Zydus Pharmaceuticals (USA), Inc., a leading generic pharmaceutical company in the United States, have entered into a settlement agreement with Depomed, Inc. to settle their ongoing patent infringement litigation related to Gralise (gabapentin) 300 mg and 600 mg tablets. The settlement permits Cadila and Zydus to begin selling generic versions of Gralise on January 1, 2024, or earlier under certain circumstances.

The agreement is subject to review by the US Department of Justice and the Federal Trade Commission, and entry of an order dismissing the litigation by the US District Court for the District of New Jersey.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.